Market Overview

UPDATE: Bank of America Merrill Lynch Initiates Coverage on Mylan with Overweight Rating

Share:
Related MYL
Watch These 7 Huge Call Purchases In Friday Trade
Mylan And Biocon Says EMA Accept Its Regulatory Submission Of Biosimilar Pegfilgrastim
Generics Keeping The Pressure On Big Pharma (Seeking Alpha)

In a report published Monday, Bank of America Merrill Lynch initiated coverage on Mylan (NASDAQ: MYL) with an Overweight rating.

BofA Merrill Lynch noted, “We initiate coverage on Mylan at OW-100%, as we see material yield and promising long-term growth prospects vs. peers within the IG Pharma subsector. Moody's and S&P upgraded Mylan to investment grade last week mainly due to its strong positioning in the generics market and favorable financial policies.”

Mylan closed on Friday at $27.11.

Latest Ratings for MYL

DateFirmActionFromTo
May 2016Leerink SwannMaintainsOutperform
Feb 2016Argus ResearchMaintainsBuy
Feb 2016Wells FargoInitiates Coverage onMarket Perform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!